Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05789862 | Behavioral Health Evaluation and Intervention Program for Patients Undergoing Craniotomy | withdrawn | N/A | 0 | University of California, San FranciscoOTHER | 0 | Aug 29, 2025 | clinicaltrials |
| NCT04580667 | Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity | withdrawn | — | 0 | DiaCarta, Inc.INDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06217016 | Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2) | withdrawn | N/A | 0 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06420908 | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | withdrawn | N/A | 0 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT06670976 | Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06555263 | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Sutro Biopharma, Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT04756765 | Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06762808 | Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 15, 2025 | clinicaltrials |
| NCT05052632 | Evaluating a New Gonadotoxic Risk Stratification System | withdrawn | — | 0 | University of Colorado, DenverOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 13, 2025 | clinicaltrials |
| NCT04118036 | Abemaciclib + Pembrolizumab In Glioblastoma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06005649 | Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Juventas Cell Therapy Ltd.INDUSTRY | 0 | Aug 8, 2025 | clinicaltrials |
| NCT06009107 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)(B-ALL) | withdrawn | Phase 1 / Phase 2 | 0 | Juventas Cell Therapy Ltd.INDUSTRY | 0 | Aug 8, 2025 | clinicaltrials |
| NCT06676917 | Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases(TUXEDO-5) | withdrawn | Phase 2 | 0 | MedSIROTHER | 0 | Aug 8, 2025 | clinicaltrials |
| NCT05717140 | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05000905 | Improving Cognition and Behavior in Pediatric Cancer Survivors Using a Novel Mindful Attention Training | withdrawn | N/A | 0 | University of California, San FranciscoOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT06474663 | A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07038915 | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1 | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Artiva Biotherapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT04615884 | Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients(CH:II) | withdrawn | N/A | 0 | Lady Davis InstituteOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05917990 | Dyadic Text-Messaging Micro-Intervention | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05634525 | Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04571710 | A Trial of SHR1258 in Patients With Biliary Tract Cancer | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jul 24, 2025 | clinicaltrials |
| NCT06501911 | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | withdrawn | Phase 1 | 0 | University of NebraskaOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT02264236 | Vaccination of Advanced-Stage Lung Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06235541 | A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Genome & CompanyINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06347185 | Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study(SupCare) | withdrawn | N/A | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jul 17, 2025 | clinicaltrials |
| NCT06161558 | Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06246786 | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) | withdrawn | Early Phase 1 | 0 | Virginia G. KaklamaniOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | withdrawn | N/A | 0 | Neena Kapoor, M.D.OTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT06086925 | A Window of Opportunity Study of Black Raspberry for Patients With HNSCC | withdrawn | Early Phase 1 | 0 | Mitchell MachtayOTHER | 0 | Jul 11, 2025 | clinicaltrials |
| NCT06498518 | A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer(PRIMUS006) | withdrawn | Phase 2 | 0 | Karen CartyOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05879484 | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05257707 | Molecular Markers in Cancers and Precancers (MOCA)(MOCA) | withdrawn | N/A | 0 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06508827 | Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 0 | Jul 9, 2025 | clinicaltrials |
| NCT04838782 | Role of Repeat Resection in Recurrent Glioblastoma | withdrawn | N/A | 0 | University of AlbertaOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT05222308 | Advanced Planning for Online Accounts and Data | withdrawn | N/A | 0 | University of Colorado, DenverOTHER | 0 | Jul 8, 2025 | clinicaltrials |
| NCT04569461 | Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)(TALON) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06013904 | Difficult PIV Placement in the Pediatric ED | withdrawn | N/A | 0 | University of Texas at AustinOTHER | 0 | Jul 4, 2025 | clinicaltrials |
| NCT04906954 | Combined Neuromuscular Electrical Stimulation and Nutritional Support for Advanced Gastrointestinal Cancer Patients.(DIGELECTROSTIM) | withdrawn | N/A | 0 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 3, 2025 | clinicaltrials |
| NCT07046481 | Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up | withdrawn | N/A | 0 | Region SkaneOTHER | 0 | Jul 1, 2025 | clinicaltrials |
| NCT06416436 | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | withdrawn | Phase 1 | 0 | University of Kansas Medical CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06545344 | Palliative Care Consultation to Improve Communication for Patients Considering Surgery for a Pancreatic Neoplasm | withdrawn | N/A | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06572189 | The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma | withdrawn | Early Phase 1 | 0 | Shanghai Changzheng HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma(BIOSELECT) | withdrawn | Phase 1 / Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT04688333 | iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma | withdrawn | — | 0 | City of Hope Medical CenterOTHER | 0 | Jun 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 29, 2025source: clinicaltrials